Apalutamide
Recent developments in advanced prostate cancer space pave way for future breakthroughs
Several practice-changing clinical trials in recent years have led to the understanding that combination treatments are most effective for patients with advanced prostate cancer.
Subsequent PFS benefit of apalutamide ‘an indicator of effective early intensive treatment’ in prostate cancer
The addition of apalutamide to androgen deprivation therapy provided a subsequent PFS benefit for men with nonmetastatic castration-resistant prostate cancer, according to results of a post-hoc analysis of the randomized phase 3 TITAN study presented at Genitourinary Cancers Symposium.
Apalutamide improves OS in nonmetastatic, castration-resistant prostate cancer
BARCELONA, Spain — Apalutamide with ongoing androgen deprivation therapy significantly improved OS compared with placebo among men with nonmetastatic, castration-resistant prostate cancer, according to updated results of the randomized phase 3 SPARTAN study presented at European Society for Medical Oncology Congress.